Although it is navigating rocky financial territory, vTv Therapeutics' appointment of a top medical officer could signal that its proprietary drug is still progressing towards Phase 3 studies. Here's how an industry veteran with 30 years of experience will help vTv treat patients with Type 1 diabetes.
